Please login to the form below

Not currently logged in
Email:
Password:

Kyowa Hakko expands portfolio with rapid bladder cancer test

Kyowa Hakkoís UK subsidiary has signed an exclusive distribution agreement with German company, Matritech to distribute and market its rapid test for bladder cancer, NMP22 BladderChek, in the UK and Ireland

Japan-headquartered Kyowa Hakkoís UK subsidiary has signed an exclusive distribution agreement with German company, Matritech to distribute and market its rapid test for bladder cancer, NMP22 BladderChek, in the UK and Ireland.

The NMP22 BladderChek test provides results in minutes rather than the usual days to confirm diagnosis of early bladder cancer and allows patients start treatment as quickly as possible, said Kyowa Hakko UK Ltd.

The test works by detecting Nuclear Matrix Protein (NMP) 22, which is expressed by tumour cells. It requires only four drops of urine to work and is unaffected by haematuria, or the presence of blood in the urine, which is a common symptom of bladder cancer.

Kyowa Hakko added that clinical studies have also found that BladderChek is more sensitive at identifying early-stage bladder cancer in combination with existing cytology cystoscopy analysis than cystoscopy alone.

Kyowa already sells a leading chemotherapy agent Mitomycin C for bladder cancer.

Hiroshi Furukawa, president of Kyowa Hakko UK, said: "Our chemotherapy agent Mitomycin C is already an established front line treatment for bladder cancer and so the addition of the new test to our portfolio will allow Kyowa Hakko to further expand its role as a market leader in the management of this disease."

Kyowa Hakkoís Q1 FY07 consolidated net sales were JPY 94.9bn (USD 813m), an increase of 10.8 per cent on Q1 FY06, driven by pharmaceutical sales. Operating income decreased by 7.3 per cent to JPY 7.5bn (USD 64.3m), due to a significant rise in R&D spend, including a one-time payment for the in-licensing of anti-cancer drug ARQ197 and despite an increase of JPY 4.3bn (USD 36.9m) in gross profit. Net income was JPY 5.3bn (USD 45.4m) up 159 per cent compared with Q1 FY06.

15th August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

segmentation_pie_thumb.jpg
If you’re not thinking segmentation, you’re not thinking
Having a background in market research I’ve been lucky to work on a number of customer segmentations in my time but working in creative communications it is still too rare...
Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
The 16th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD)conference took place at the Hilton Madrid Airport hotel on 15–16 May 2018....
Londonvelophobia (fear of cycling in London) – debunked
...

Infographics